- Enveric Biosciences (ENVB, Financial) secures its second U.S. patent allowance for proprietary mescaline derivatives.
- The patent enhances Enveric's intellectual property portfolio for treating psychiatric disorders.
- The newly allowed compounds are designed as non-hallucinogenic alternatives for mental health therapies.
Enveric Biosciences (ENVB), a biotechnology firm focused on neuroplastogenic therapeutics, has received a second Notice of Allowance from the United States Patent and Trademark Office for its EVM401 Series. This expansion strengthens the company's patent portfolio in developing treatments for psychiatric and neurological conditions. The approved application titled “Substituted N-Propylamine Fused Heterocyclic Mescaline Derivatives” covers a series of unique, structurally distinct benzodioxole derivatives designed as non-hallucinogenic modulators of neurotransmitters.
“With this second patent allowance for the EVM401 Series, Enveric continues to solidify its position as a leader in developing first-in-class neuroplastogenic small-molecule therapeutics,” noted Joseph Tucker, Ph.D., Director and CEO of Enveric. These innovative compounds are engineered to promote neuroplasticity without inducing hallucinations, thus supporting scalable outpatient care.
Unlike traditional methylone, which lacks exclusivity due to its publicly known structure, Enveric’s novel compounds offer a secured pathway for regulatory and commercial development. Future preclinical testing is anticipated to further investigate these compounds' efficacy and safety for conditions such as PTSD.
Enveric is committed to advancing its pipeline of non-hallucinogenic neuroplastogens, aligning with modern mental health treatment demands. The company seeks to further develop its lead molecule, EB-003, towards clinical trials while exploring out-licensing opportunities for other novel drug candidates.
